NASDAQ:VRNA - VERONA PHARMA P/S Stock Price, Forecast & News

VERONA PHARMA P/S trades on the NASDAQ under the ticker symbol "VRNA."

VERONA PHARMA P/S (NASDAQ:VRNA) released its quarterly earnings results on Tuesday, November, 5th. The company reported ($0.95) EPS for the quarter, missing analysts' consensus estimates of ($0.89) by $0.06. View VERONA PHARMA P/S's Earnings History.

VERONA PHARMA P/S is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for VERONA PHARMA P/S.

2 equities research analysts have issued 12 month target prices for VERONA PHARMA P/S's stock. Their forecasts range from $17.00 to $58.00. On average, they anticipate VERONA PHARMA P/S's stock price to reach $37.50 in the next twelve months. This suggests a possible upside of 839.8% from the stock's current price. View Analyst Price Targets for VERONA PHARMA P/S.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VERONA PHARMA P/S in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VERONA PHARMA P/S.

Media stories about VRNA stock have been trending somewhat positive on Friday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. VERONA PHARMA P/S earned a daily sentiment score of 1.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for VERONA PHARMA P/S.

VERONA PHARMA P/S saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 600 shares, an increase of 500.0% from the October 31st total of 100 shares. Based on an average trading volume of 4,000 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.0% of the company's stock are sold short. View VERONA PHARMA P/S's Current Options Chain.

Some companies that are related to VERONA PHARMA P/S include Spero Therapeutics (SPRO), Mirum Pharmaceuticals (MIRM), Abeona Therapeutics (ABEO), XOMA (XOMA), Athersys (ATHX), Satsuma Pharmaceuticals (STSA), Protagonist Therapeutics (PTGX), Syros Pharmaceuticals (SYRS), Ovid Therapeutics (OVID), Cerecor (CERC), Aquestive Therapeutics (AQST), Ocular Therapeutix (OCUL), Nature's Sunshine Products (NATR), Affimed (AFMD) and AcelRx Pharmaceuticals (ACRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other VERONA PHARMA P/S investors own include Ligand Pharmaceuticals (LGND), Nightstar Therapeutics (NITE), Supernus Pharmaceuticals (SUPN), Teva Pharmaceutical Industries (TEVA), MOTIF BIO PLC/S (MTFB), SUMMIT THERAPEU/S (SMMT), OASMIA PHARMACE/ADR (OASM), Portola Pharmaceuticals (PTLA), REDHILL BIOPHAR/S (RDHL) and Sorrento Therapeutics (SRNE).

(VRNA) raised $61 million in an initial public offering (IPO) on Thursday, April 27th 2017. The company issued 4,500,000 shares at $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

VERONA PHARMA P/S's stock is owned by many different of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.23%) and IHT Wealth Management LLC (0.16%).

VRNA stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc. and IHT Wealth Management LLC.

Shares of VRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VRNA stock can currently be purchased for approximately $3.99.

VERONA PHARMA P/S has a market capitalization of $52.55 million. The company earns $-26,560,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. VERONA PHARMA P/S employs 22 workers across the globe.View Additional Information About VERONA PHARMA P/S.

The official website for VERONA PHARMA P/S is http://www.veronapharma.com/.

VERONA PHARMA P/S's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company can be reached via phone at 44-20-3283-4200 or via email at [email protected]